Wasaburo Koizumi - Concepedia

Author

Wasaburo Koizumi

Also Known As

A Shibuya, Eiji Miyata, K. Wasaburo, Koizumi Wasaburo, Makoto Takahashi, Satoshi Tanabe, The JACCRO and KCSG Study Group, W Koizumi, W. Koizumi, W., Koizumi

501

Publications

11K

Citations

H-Index

134

Concepts

All Affiliations

Kitasato University Kitasato University Hospital Kitasato University East Hospital National Cancer Center Hospital East Aichi Cancer Center

About

Wasaburo Koizumi is an author at Kitasato University specializing in medicine, oncology, and gastroenterology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	94	5.8K
2	Health Sciences	17	24	752
3	Engineering	3	3	77
4	Education	1	1	34
5	Public Health	1	1	19

Wasaburo Koizumi

191

Publications

9.8K

Citations

H-Index

Page 1

	Year	Citations
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara, The Lancet Oncology Surgical OncologySpirits TrialGastrointestinal OncologyAdvanced Gastric CancerMedicine	2008	1.9K
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Narikazu Boku, Seiichiro Yamamoto, Haruhiko Fukuda, The Lancet Oncology OncologyCisplatin Versus S-1Gastrointestinal OncologyMedicineRandomised Phase 3	2009	591
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer Wasaburo Koizumi, Minoru Kurihara, Shuji Nakano, Oncology	2000	440
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Wasaburo Koizumi, Satoshi Tanabe, Katsunori Saigenji, British Journal of Cancer	2003	249
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani, The Lancet. Gastroenterology & hepatology Gastrointestinal OncologyMedicineAdvanced Gastric CancerPharmacologyClinical Trials	2017	215
Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912) Narikazu Boku, Suguru Yamamoto, Kuniaki Shirao, Journal of Clinical Oncology OncologyLba4513 BackgroundsGastrointestinal OncologyAdvanced Gastric CancerVersus Combination	2007	158
Clinical outcome of endoscopic aspiration mucosectomy for early stage gastric cancer Satoshi Tanabe, Wasaburo Koizumi, Hiroyuki Mitomi, Gastrointestinal Endoscopy Endoscopic Aspiration MucosectomyMedicineGastroenterologySurgeryUpper Gastrointestinal Surgery	2002	141
Pharmacodynamic Studies of Gefitinib in Tumor Biopsy Specimens From Patients With Advanced Gastric Carcinoma Federico Rojo, Josep Tabernero, Joan Albanell, Journal of Clinical Oncology	2006	136
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis Takahide Nakazawa, Hisashi Hidaka, Akitaka Shibuya, BMC Gastroenterology	2014	128
Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a retrospective comparison with conventional endoscopic resection in a single center Satoshi Tanabe, Kenji Ishido, Katsuhiko Higuchi, Gastric Cancer Single CenterGastroenterologyEus-guided GastroenterostomySurgeryUpper Gastrointestinal Surgery	2013	126

Page 1